CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 479 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $33,756 | -20.8% | 625 | 0.0% | 0.00% | -50.0% |
| Q1 2024 | $42,600 | +8.9% | 625 | 0.0% | 0.00% | -50.0% |
| Q4 2023 | $39,125 | +37.9% | 625 | 0.0% | 0.00% | +33.3% |
| Q3 2023 | $28,369 | -19.1% | 625 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $35,088 | +24.1% | 625 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $28,269 | +11.3% | 625 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $25,406 | – | 625 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |